Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01511900 · ClinicalTrials.gov registry record · Phase 1
A Multiple Ascending Dose Study of CAT-1004 in Patients With Type 2 Diabetes
A Phase 1 study, sponsored by Catabasis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT01511900 is a Phase 1 study that has completed, run by Catabasis Pharmaceuticals. The registered enrollment target is 44 participants.
The verdict
NCT01511900, a Phase 1 study, has completed, sponsored by Catabasis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the safety of escalating multiple doses over 2 weeks of CAT 1004 compared to placebo in patients with Type 2 diabetes (T2D). Secondary objectives include evaluation of the pharmacokinetics (PK) and pharmacodynamics of escalating multiple doses of CAT-1004 in patients with T2D.
Interventions
- DRUG Placebo
- DRUG CAT 1004
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2011-12 |
| Est. Completion | 2012-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01511900
The ClinicalTrials.gov registry entry for NCT01511900 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Catabasis Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01511900 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01511900 about?
NCT01511900 is a clinical study titled "A Multiple Ascending Dose Study of CAT-1004 in Patients With Type 2 Diabetes". The primary objective of the study is to evaluate the safety of escalating multiple doses over 2 weeks of CAT 1004 compared to placebo in patients with Type 2 diabetes (T2D). Secondary objectives include evaluation of the pharmacokinetics (PK) and pharmacodynamics of escalating multiple doses of CA...
What is the current status of trial NCT01511900?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2011-12. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01511900?
The interventions under investigation include: Placebo (DRUG), CAT 1004 (DRUG).
Who is sponsoring clinical trial NCT01511900?
This trial is sponsored by Catabasis Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.